Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DYAI Stock Forecast 2025-2026
$1.18
Current Price
$36.41M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DYAI Price Targets
+662.7%
To High Target of $9.00
+535.6%
To Median Target of $7.50
+408.5%
To Low Target of $6.00
DYAI Price Momentum
-5.6%
1 Week Change
-13.9%
1 Month Change
-20.8%
1 Year Change
-32.6%
Year-to-Date Change
-55.8%
From 52W High of $2.67
+26.9%
From 52W Low of $0.93
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Dyadic International (DYAI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on DYAI and similar high-potential opportunities.
Latest DYAI Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, DYAI has a bullish consensus with a median price target of $7.50 (ranging from $6.00 to $9.00). Currently trading at $1.18, the median forecast implies a 535.6% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Vernon Bernardino at HC Wainwright & Co., suggesting a 408.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DYAI Analyst Ratings
1
Buy
0
Hold
0
Sell
DYAI Price Target Range
Low
$6.00
Average
$7.50
High
$9.00
Current: $1.18
Latest DYAI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DYAI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $6.00 |
| Jul 8, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $6.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $6.00 |
| May 24, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $6.00 |
| Feb 3, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $6.00 |
| Jul 18, 2022 | Dawson James | Jason Kolbert | Neutral | Downgrade | $0.00 |
| Apr 5, 2022 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $6.00 |
| Dec 17, 2021 | HC Wainwright & Co. | Buy | Initiates | $0.00 |
Dyadic International Inc. (DYAI) Competitors
The following stocks are similar to Dyadic International based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Dyadic International Inc. (DYAI) Financial Data
Dyadic International Inc. has a market capitalization of $36.41M with a P/E ratio of -5.9x. The company generates $3.50M in trailing twelve-month revenue with a -166.2% profit margin.
Revenue growth is +19.1% quarter-over-quarter, while maintaining an operating margin of -186.1% and return on equity of -139.2%.
Valuation Metrics
Market Cap
$36.41M
Enterprise Value
$31.31M
P/E Ratio
-5.9x
PEG Ratio
-3.7x
Price/Sales
10.4x
Growth & Margins
Revenue Growth (YoY)
+19.1%
Gross Margin
+56.8%
Operating Margin
-186.1%
Net Margin
-166.2%
EPS Growth
+19.1%
Financial Health
Cash/Price Ratio
+26.1%
Current Ratio
4.0x
Debt/Equity
205.1x
ROE
-139.2%
ROA
-40.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Dyadic International Inc. (DYAI) Business Model
About Dyadic International Inc.
What They Do
Biotechnology company specializing in enzyme technology.
Business Model
Dyadic International generates revenue by commercializing its proprietary C1 cell line technology, which enhances the production of biopharmaceuticals, including vaccines, enzymes, and therapeutic proteins. By offering a more efficient and cost-effective alternative to traditional production methods, the company serves various sectors, including pharmaceuticals, agriculture, and industrial biotechnology.
Additional Information
Headquartered in Jupiter, Florida, Dyadic partners with global entities to foster research and development. The company's focus on innovation and scalability positions it strategically within the biotechnology sector, contributing to advancements in the production of essential biochemical compounds.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
6
CEO
Mr. Mark A. Emalfarb
Country
United States
IPO Year
2018
Website
www.dyadic.comDyadic International Inc. (DYAI) Latest News & Analysis
Latest News
Quick Summary
Dyadic International, Inc. (Nasdaq: DYAI) will have CEO Mark Emalfarb present at the 2025 World Vaccine Congress in Washington, D.C., highlighting its microbial production platforms for protein manufacturing.
Why It Matters
Dyadic's presentation at a major vaccine congress highlights its strategic focus on biotechnology, potentially boosting investor confidence in its growth and innovation in vaccine development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dyadic International, Inc. will hold its Q4 2024 Earnings Conference Call on March 26, 2025, at 5:00 PM ET, featuring key executives and analysts from various firms.
Why It Matters
The earnings call provides insights into Dyadic International's financial health and future strategies, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Dyadic International (NASDAQ: DYAI) reported strong progress in 2024, focusing on its Dapibus™ and C1 protein production platforms for vaccines, therapeutics, and non-pharmaceutical uses.
Why It Matters
Dyadic's financial results and progress in commercializing its protein production platforms signal potential revenue growth, attracting investor interest in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
1 month ago
Quick Summary
Dyadic International, Inc. (Nasdaq: DYAI) will report its 2024 financial results and hold a corporate update call on March 26, 2025, focusing on its protein manufacturing for various applications.
Why It Matters
Dyadic's upcoming financial results and conference call could reveal insights into its performance and growth potential, influencing investor sentiment and stock price volatility.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dyadic International, Inc. (Nasdaq: DYAI) announced its management's participation in key industry events globally, focusing on large-scale protein manufacturing for vaccines and therapeutics.
Why It Matters
Dyadic's participation in key industry events highlights its market visibility and potential partnerships, which could enhance growth prospects and investor confidence in its biotechnology initiatives.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
3 months ago
Quick Summary
Dyadic International, Inc. (Nasdaq: DYAI) is advancing its Alternative Proteins business and is exploring its C1 platform for vaccines and diagnostics, targeting infectious diseases like H5N1 Avian Influenza.
Why It Matters
Dyadic's focus on alternative proteins and its C1 platform for vaccines and diagnostics positions it to capitalize on rising demand for innovative solutions in health and agriculture, enhancing growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DYAI Stock
What is Dyadic International Inc.'s (DYAI) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Dyadic International Inc. (DYAI) has a median price target of $7.50. The highest price target is $9.00 and the lowest is $6.00.
Is DYAI stock a good investment in 2025?
According to current analyst ratings, DYAI has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DYAI stock?
Wall Street analysts predict DYAI stock could reach $7.50 in the next 12 months. This represents a 535.6% increase from the current price of $1.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dyadic International Inc.'s business model?
Dyadic International generates revenue by commercializing its proprietary C1 cell line technology, which enhances the production of biopharmaceuticals, including vaccines, enzymes, and therapeutic proteins. By offering a more efficient and cost-effective alternative to traditional production methods, the company serves various sectors, including pharmaceuticals, agriculture, and industrial biotechnology.
What is the highest forecasted price for DYAI Dyadic International Inc.?
The highest price target for DYAI is $9.00 from at , which represents a 662.7% increase from the current price of $1.18.
What is the lowest forecasted price for DYAI Dyadic International Inc.?
The lowest price target for DYAI is $6.00 from Vernon Bernardino at HC Wainwright & Co., which represents a 408.5% increase from the current price of $1.18.
What is the overall DYAI consensus from analysts for Dyadic International Inc.?
The overall analyst consensus for DYAI is bullish. Out of 3 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.50.
How accurate are DYAI stock price projections?
Stock price projections, including those for Dyadic International Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 2:33 PM UTC